Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
Sign Up to like & getrecommendations! Published in 2020 at "Naunyn-Schmiedeberg's Archives of Pharmacology"
DOI: 10.1007/s00210-020-01873-7
Abstract: The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats. The effects of empagliflozin were compared with the standard medications for HF,… read more here.
Keywords: normoglycemic rats; group; heart failure; empagliflozin ... See more keywords
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-017-0573-0
Abstract: IntroductionWe characterized the safety and tolerability of empagliflozin in patients with type 2 diabetes (T2DM) randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in clinical trials.MethodsPooled data were analyzed from patients with T2DM treated… read more here.
Keywords: 100 patient; empagliflozin patients; safety tolerability; empagliflozin ... See more keywords
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes Therapy"
DOI: 10.1007/s13300-022-01221-3
Abstract: International and Danish guidelines recommend the use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors already in second line in the management of type 2 diabetes (T2D). The objective… read more here.
Keywords: cost effectiveness; empagliflozin; cost; semaglutide ... See more keywords
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.01.056
Abstract: BACKGROUND Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be explained exclusively by its antihyperglycemic activity. OBJECTIVES The hypothesis was that empagliflozin's cardiac… read more here.
Keywords: empagliflozin ameliorates; empagliflozin; left ventricular; heart failure ... See more keywords
Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2020.11.008
Abstract: BACKGROUND Large clinical trials established the benefits of SGLT2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely explained by… read more here.
Keywords: trial; empagliflozin; hfref patients; placebo ... See more keywords
Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Sign Up to like & getrecommendations! Published in 2020 at "Kidney international"
DOI: 10.1016/j.kint.2020.12.013
Abstract: Chronic kidney disease (CKD) promotes development of cardiac abnormalities and is highly prevalent in patients with heart failure, particularly in those with preserved ejection fraction. CKD is associated with endothelial dysfunction, however, whether CKD can… read more here.
Keywords: cardiomyocyte relaxation; relaxation contraction; empagliflozin; nitric oxide ... See more keywords
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
Sign Up to like & getrecommendations! Published in 2022 at "Redox Biology"
DOI: 10.1016/j.redox.2022.102288
Abstract: Mitophagy preserves microvascular structure and function during myocardial ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect mitochondria. We explored whether empagliflozin could reduce cardiac microvascular I/R injury by enhancing mitophagy. In mice, I/R… read more here.
Keywords: ischemia reperfusion; empagliflozin; mitophagy; fundc1 ... See more keywords
COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)31291-4
Abstract: EMPRISE is a study program on the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor (SGLT2i), in routine care across a spectrum of cardiovascular (CV) baseline risk using real-world data from 2… read more here.
Keywords: empagliflozin; emprise study; effectiveness; effectiveness safety ... See more keywords
Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-02895-7
Abstract: The present study considered the pharmacokinetic evaluation of empagliflozin after administration to Egyptian volunteers, and the results were compared with other ethnic populations. The FDA recognizes that standard methods of defining racial subgroups are necessary… read more here.
Keywords: pharmacokinetic evaluation; ethnic populations; study; empagliflozin ... See more keywords
The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical science"
DOI: 10.1042/cs20220447
Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to delay diabetic kidney disease (DKD) progression on top of the standard of care with the renin-angiotensin system (RAS) blockade. The molecular mechanisms underlying the synergistic effect of… read more here.
Keywords: top ras; empagliflozin; map17 regulated; ras blockade ... See more keywords
The antioxidative effects of empagliflozin on high glucose‑induced epithelial-mesenchymal transition in peritoneal mesothelial cells via the Nrf2/HO-1 signaling
Sign Up to like & getrecommendations! Published in 2022 at "Renal Failure"
DOI: 10.1080/0886022x.2022.2118066
Abstract: Abstract High glucose (HG)-induced epithelial-mesenchymal transition (EMT) and oxidative stress play an important role in peritoneal fibrosis, which could be regulated by the nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway. This study… read more here.
Keywords: empagliflozin; stress; glucose induced; oxidative stress ... See more keywords